



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

October 15, 2018

Corporate Relationship Department  
M/s. BSE Ltd  
Dalal Street, Fort  
Mumbai- 400 001

Manager – Listing  
M/s. National Stock Exchange of India Ltd  
“Exchange Plaza”, Bandra – Kurla Complex  
Bandra (E) Mumbai -400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir

Please find enclosed herewith the Press Release for your information.

Thanking you

Yours faithfully  
For **NATCO Pharma Limited**

  
M Adinarayana

Company Secretary &  
Vice President (Legal & Corp Affairs)



# Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref: PR/ 7 /2018-2019

Press Release

## Court Affirms Prior Decisions Finding Copaxone® 40 mg/mL Patents Invalid- a milestone for NATCO and its marketing partner Mylan

**Hyderabad, India, October 15<sup>th</sup>, 2018**

NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce that the United States Court of Appeals for the Federal Circuit has affirmed the District of Delaware's decision that Teva's Copaxone® 40 mg/mL dosing patents are invalid as obvious. The Federal Circuit also affirmed today the final written decisions issued by the Patent Trial and Appeal Board (PTAB) in three inter partes reviews filed by Natco's marketing partner, Mylan, related to the same patents.


These were the last remaining patent infringement cases Mylan was defending in the U.S. relating to Glatiramer Acetate Injection 40mg/mL. Today's decisions are important milestones as we continue to focus our efforts on meeting the needs of multiple sclerosis patients in the U.S. The invalidated patents are U.S. Patent Numbers 8,232,250; 8,399,413; 8,969,302; and 9,155,776, which are owned by Yeda Research & Development Co., Ltd. and licensed to Teva Pharmaceuticals Industries, Ltd.

Copaxone® is the most prescribed MS treatment for relapsing forms of MS in the U.S. with brand sales for the 20 mg/mL dose of approximately \$527 million and for the 40 mg/mL dose of approximately \$2.86 billion for the 12 months ending Aug. 31, 2018, according to IQVIA. Approximately 400,000 individuals in the U.S. have MS and relapsing MS accounts for 85% of initial MS diagnoses.

---

Forwarded for favour of publication

For NATCO Pharma Limited

  
M. Adinarayana

Company Secretary &  
Vice President (Legal and Corp Affairs)